<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952625</url>
  </required_header>
  <id_info>
    <org_study_id>RJ116/N013</org_study_id>
    <nct_id>NCT02952625</nct_id>
  </id_info>
  <brief_title>PET/MR in Radiotherapy for Head and Neck Cancer Pilot</brief_title>
  <official_title>An Exploratory Study to Assess the Feasibility of Incorporating PET/MR in the Radiotherapy Pathway of Patients With Head and Neck Cancer and Guide Adaptive Dose Escalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot non-intervention study that aims to introduce PET/MRI, a state of the art new&#xD;
      imaging technique, into the radiotherapy treatment pathway of patients with head and neck&#xD;
      cancer. Ultimately the investigators aim to establish appropriate scanning and image&#xD;
      registration protocols, to allow progression to a randomized trial of adaptive radiotherapy&#xD;
      dose escalation. The latter is thought to potentially improve outcomes in this group.&#xD;
&#xD;
      Ten patients with squamous cell carcinoma (SCC) of the oropharynx, hypopharynx and larynx,&#xD;
      planned for radical treatment with radiotherapy (+/-chemotherapy), will be recruited. Study&#xD;
      participants will have two PET/MRI scans, with the radiotherapy immobilization devices in&#xD;
      situ. The first will be done prior to the start of radiotherapy, the second half way through&#xD;
      treatment.&#xD;
&#xD;
      Image quality will be assessed by comparing to standard diagnostic scans and different&#xD;
      registration methods will be compared to establish the best way of incorporating PET/MR image&#xD;
      data into the radiotherapy planning system. Patient tolerability and workflow considerations&#xD;
      will also be qualitatively assessed. Furthermore, a planning study will be conducted to&#xD;
      establish relevant treatment protocols for a subsequent dose escalation trial.&#xD;
&#xD;
      PET/MRI is an exciting new technology with a lot of potential in the context of adaptive&#xD;
      radiotherapy dose escalation. Within this pilot study the investigators aim to address the&#xD;
      technical challenges of using it in this context prior to proceeding to a randomized trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of scans where image quality is sufficient to characterise the primary tumour, assessed qualitatively by an experienced radiologist and oncologist</measure>
    <time_frame>6 months following study completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients that tolerated the full scanning protocol, assessed by tailored patient questionnaire</measure>
    <time_frame>6 months following study completion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm imaging study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging</intervention_name>
    <description>Single arm Imaging (PET/MR) study</description>
    <arm_group_label>Single arm imaging study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written, voluntary, informed consent&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          -  Life expectancy &gt; 12 months&#xD;
&#xD;
          -  Histologically proven SCC of the oropharynx, hypopharynx and larynx&#xD;
&#xD;
          -  Radical radiotherapy +/- chemotherapy indicated as the primary treatment modality&#xD;
&#xD;
          -  Visible disease (&gt;1cm) at the primary site on any imaging modality performed within 4&#xD;
             weeks of starting radiotherapy treatment&#xD;
&#xD;
          -  Staging PET/CT and diagnostic MRI of the head and neck images need to be available for&#xD;
             comparison.&#xD;
&#xD;
          -  Adequate organ function and absence of other major concurrent illness, allowing the&#xD;
             patient to tolerate scanning regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Impaired renal function (serum creatinine of &gt; 200)&#xD;
&#xD;
          -  Severely impaired liver function&#xD;
&#xD;
          -  Patients with allergies or contra-indications to the radio-tracer and/or contrast&#xD;
             agent used in the study&#xD;
&#xD;
          -  Severe claustrophobia or inability to tolerate PET or MRI scans&#xD;
&#xD;
          -  General contra-indications to MRI, as defined in MRI safety departmental protocols&#xD;
&#xD;
          -  Serious inter-current conditions or other non-malignant illnesses that are&#xD;
             uncontrolled or whose control may be affected by participation in this study&#xD;
&#xD;
          -  Any patient who has urinary or faecal incontinence&#xD;
&#xD;
          -  ECOG Performance Status ≥ 3&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Guerrero Urbano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's &amp; St Thomas' NHS Foundation Trust, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

